Insight into the different treatment options to reduce the risk of stroke in AF patients

Treatments to Reduce the Risk of Stroke in AF

Oral Anticoagulants

The most common treatment for managing AF-related stroke risk is the use of anticoagulants, such as warfarin (Coumadin®) and novel oral anticoagulants (NOACs).

Warfarin and NOACs effectively reduce the risk of cardioembolic stroke, however they are not well tolerated by some patients and carry a risk for bleeding complications.

The limits of oral anticoagulants include:

  • Risk of bleeding
  • High rate of discontinuation (at 2 years, 50% of patients on VKA and 30% on NOAC treatment)1
  • Interactions with certain foods and medications (warfarin)
  • Frequent blood tests and dose adjustment (warfarin)
Illustration of heart with WATCHMAN FLX Device

WATCHMAN FLX implant procedure

The WATCHMAN FLX device offers a breakthrough approach to reduce the risk of stroke. Most blood clots in people with AF develop in the left atrial appendage (LAA).

WATCHMAN FLX acts as a barrier to keep these blood clots from escaping the LAA, going into the bloodstream, blocking a blood vessel, and causing a stroke.

Considering referring a patient for LAA Closure?
Hear the rationale from expert physicians

Learn more about a permanent solution designed
to reduce the risk of stroke.

Innovative One-Time Solution

1. Martinez et al. Thromb Haemost 2015;114: In press.

The law restricts these devices to sale by or on the order of a physician. Indications, contraindications, warnings and instructions for use can be found in the product labelling supplied with each device.
Products shown for INFORMATION purposes only and may not be approved or for sale in certain countries.
This material not intended for use in France.